Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382221 · ClinicalTrials.gov registry record · NA
Breathe 2 Project 3: Comprehensive Chronic Care
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 979
- Enrollment target
NCT05382221: Completed NA study, sponsored by University of Wisconsin, Madison.
NCT05382221 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 979 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382221, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 979 participants
- Enrollment target
Study Summary
This study will evaluate Comprehensive Chronic Care (CCC), a healthcare treatment approach designed to increase smoking treatment engagement and abstinence among primary care patients who smoke. This research will compare CCC with Standard of Care (SC) on the following outcomes: abstinence at 18 months (primary outcome), treatment reach, and cost-effectiveness. Participation in the study will last 18 months.
Primary Outcome
Group differences in abstinence at 18 months will be evaluated using logistic regression.
Interventions
- OTHER Standard Care
- OTHER Comprehensive Chronic Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 979 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2025-09-25 |
| Phase | NA |
What the finished NCT05382221 record still lists
NCT05382221 is an interventional study that assigns participants to a tested intervention. The registered 979 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.
NCT05382221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05382221 about?
NCT05382221 is a clinical study titled "Breathe 2 Project 3: Comprehensive Chronic Care". This study will evaluate Comprehensive Chronic Care (CCC), a healthcare treatment approach designed to increase smoking treatment engagement and abstinence among primary care patients who smoke. This research will compare CCC with Standard of Care (SC) on the following outcomes: abstinence at 18 mon...
What is the current status of trial NCT05382221?
This trial is currently completed. It is a NA study. The enrollment target is 979 participants. The study started on 2022-08-08. Estimated completion is 2025-09-25.
What interventions are being tested in trial NCT05382221?
The interventions under investigation include: Standard Care (OTHER), Comprehensive Chronic Care (OTHER).
Who is sponsoring clinical trial NCT05382221?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05382221's enrollment target sits among peer trials
979 122nd of 2000 higher than 1,879 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07184996 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI